Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sudha Pandit

Gastroenterology Shreveport, LA Medical Doctor

NPI 1548601222 CMS profile 1418763

1541 Kings Hwy, Shreveport, LA 71103

Open in the dashboard

General payments

$7,762

383 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$15,000 paid to institutions, not to them · program year 2021

Through program year 2025, Sudha Pandit of Shreveport, LA is reported in the CMS Open Payments database as having received $7,762 across 383 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $15,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 76th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,960 59
2024 General $1,334 67
2023 General $1,336 78
2022 General $1,202 69
2021 General $1,043 60
2020 General $356 22
2019 General $531 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sudha Pandit
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Sudha Pandit were reported at $1,960. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Sudha Pandit Gastroenterology median Middle half National median
2019 $531 $417 $126–$1,100 $163
2020 $356 $224 $74–$624 $114
2021 $1,043 $352 $106–$1,054 $132
2022 $1,202 $448 $129–$1,270 $149
2023 $1,336 $533 $150–$1,390 $160
2024 $1,334 $605 $160–$1,606 $164
2025 $1,960 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,139 130 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $815 52 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $718 41 payments
  4. Janssen Biotech, Inc. $712 40 payments
  5. Medtronic, Inc. $660 1 payment
  6. Pfizer Inc. $572 33 payments
  7. Gilead Sciences, Inc. $442 19 payments
  8. Boston Scientific Corporation $257 9 payments
  9. Daiichi Sankyo Inc. $224 13 payments
  10. Celgene Corporation $198 9 payments
  11. Other $1,024 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,004 376 payments
  2. Consulting Fee $660 1 payment
  3. Education $70 4 payments
  4. Gift $27 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,004 68 payments
  2. HUMIRA $891 49 payments
  3. ENTYVIO $806 51 payments
  4. XIFAXAN $718 41 payments
  5. ManoScan $660 1 payment
  6. SKYRIZI Immunology $604 37 payments
  7. STELARA $586 34 payments
  8. XELJANZ $502 28 payments
  9. INJECTAFER $224 13 payments
  10. SKYRIZI Immunology $209 16 payments
  11. Other $2,383 106 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

211

Median for Internal Medicine: 777

Drug cost

$5,659

Median for Internal Medicine: $73,373

Branded share of claims

80.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 31 $2,054
Gavilyte-C Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 77 $1,245
Sucralfate Generic 11 $1,098
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 30 $496
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 31 $496
Omeprazole Generic 12 $190
Pantoprazole Sodium Generic 19 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$31,248

Medicare's payments for the services billed

Medicare patients

194

Average age 68

Services billed

376

116 women, 78 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 45%
Arthritis 40%
Depression 33%
Chronic kidney disease 31%
Ischemic heart disease 30%
Heart failure 28%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$187 — —
STELARA
$165 — —
ENTYVIO
$152 — —
SKYRIZI
$137 — —
TREMFYA
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

383 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record